Monitor for enrollment updates and regulatory milestones for the Canadian Phase 3 trial (2027 start) and Australian commercial shipments (by end of 2026). No revenue or earnings data in this filing — share price reaction likely driven by sentiment around psychedelic therapy regulatory progress rather than financials.
Price Chart
Executive Summary
Optimi Health Corp. announced completion of an MDMA production batch to supply a proposed Canadian Phase 3 PTSD trial (up to 100 veterans/frontline workers, expected to begin 2027), a MAPS-partnered clinical trial in Israel, and a commercial export to Australia before end of 2026. The filing is a routine operational update with no financial data — all material milestones are forward-looking and contingent on regulatory approvals and trial execution.
Key Facts
- Completed MDMA finished drug product batch manufactured at GMP facility in Princeton, British Columbia under Health Canada Drug Establishment Licence.
- Batch to supply proposed Phase 3 PTSD trial in Canada (up to 100 participants, veterans/frontline workers, primary endpoint CAPS-5, expected start 2027).
- Batch to supply commercial export to Australia before end of 2026 and a previously announced MAPS-partnered clinical trial in Israel.
- Optimi has received Australian import permits; >750 clinicians completed Mind Medicine Australia's psychedelic therapy certificate; no reported serious adverse events since commercial supply began in 2024.
- No MDMA drug products have received market authorization by Health Canada; safety and efficacy still under investigation in Canada.
Financial Impact
No financial figures disclosed; revenue, costs, or deal values not provided.
Risk Factors
- Phase 3 trial has not yet begun; enrollment, regulatory approvals, and data readouts are uncertain and years away.
- No Health Canada market authorization for MDMA products; commercial revenue in Australia depends on continued prescription scheme access and reimbursement.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006705 |
| Document: f6k_102026.htm | 0001171843-26-006705 |
| Document: 0001171843-26-006705-index-headers.html | 0001171843-26-006705 |
| Document: 0001171843-26-006705-index.html | 0001171843-26-006705 |
| Document: 0001171843-26-006705.txt | 0001171843-26-006705 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $3.12 | awaiting T+5 | — | $3.04 (−2.56%) |
Oct 20, 2026 7d ago | 6-K | $3.36 $3.04 | ▼ −9.52% | ▼ −9.60% | $3.04 (−9.52%) |
Oct 7, 2026 20d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.04 (−24.75%) |
Oct 5, 2026 22d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.04 (−26.39%) |
Sep 29, 2026 28d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.04 (−36.40%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.04 (−38.71%) |
Sep 22, 2026 5w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.04 (−38.71%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.04 (−37.96%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.04 (−32.44%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.04 (+37.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers